

# Medical Abortion Infections Lowered by 93%

BY HEIDI SPLETE

**T**he rate of serious infections in women who had medical abortions decreased by 93% after a protocol change from vaginal to buccal misoprostol combined with routine antibiotics, based on data from more than 200,000 women.

From 2001 through March 2006, Planned Parenthood health centers in the United States managed medical abortions with a combination of oral mifepristone followed by vaginal misoprostol 24-48 hours later, said Mary Fjerstad of Chapel Hill, N.C., a nurse practitioner with Planned Parenthood.

But at the end of March 2006, in re-

**The change in protocol from vaginal to buccal misoprostol, along with widespread use of antibiotics, significantly reduced serious infections in women who underwent medical abortions.**

sponse to several deaths from bacterial infections after medical abortions, the organization switched its protocol from vaginal to buccal misoprostol (200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours later), in addition to either routine antibiotics or screening and treatment for chlamydia. In 2007, Planned Parenthood required all its centers to provide antibiotics for all patients undergoing medical abortions (N. Engl. J. Med. 2009;361:145-51).

In this study, Ms. Fjerstad and her colleagues reviewed data from 227,823 women who had medical abortions at 78 Planned Parenthood sites throughout the United States between 2005 and 2008. The data were divided into four time periods based around changes in protocol.

In period 1 (Jan. 1, 2005, through March 31, 2006), the health care centers used vaginal misoprostol and standard antiseptic measures for fetuses through 63 days' gestation.

In period 2 (April 1, 2006, through June 30, 2007), they used buccal misoprostol for fetuses through 56 days' gestation (or, rarely, oral misoprostol through 49 days' gestation); some centers administered doxycycline to all patients, while others screened for sexually transmitted infections and treated them.

In period 3 (July 1, 2007, through Dec. 31, 2007), the health care centers used buccal misoprostol and routine doxycycline for fetuses through 56 days' gestation.

In period 4 (Jan. 1, 2008, through June 30, 2008), the centers used buccal misoprostol and routine doxycycline for fetuses through 63 days' gestation. The doxycycline regimen, when used, was 100 mg orally twice a day for 7 days.

A total of 92 serious infections were reported in the study population. Of these, most occurred in period 1 (67) and period 2 (20). Two serious infections occurred in

period 3, and three occurred in period 4. The relative decrease in infections was statistically significant between periods 1 and 4. In addition, the rate of serious infection decreased significantly between periods 1 and 2 and between periods 2 and 3. The change in serious infection rate was not significant between periods 3 and 4.

"Because there was no significant increase in the rate of serious infection from period 3 to period 4, it is unlikely

that a decline in the maximum gestational age from 63 days in period 1 to 56 days in period 2 explains the decline over time in the rates of serious infection observed in both groups," the researchers noted.

The patients also were evaluated in two groups based on whether they received antibiotics only if they tested positive for a sexually transmitted infection (group 1) or received antibiotics as part of the treatment protocol (group 2). The

decline in serious infection rates was significantly greater in group 2, compared with group 1 between periods 1 and 2 (93% vs. 61%), the researchers noted.

The results were limited by the retrospective nature of the study and the lack of long-term follow-up data, they said.

One of Ms. Fjerstad's coauthors, Dr. Vanessa Cullins, was also employed by Planned Parenthood at the time of the study. No other conflicts were reported. ■

*Confidence*  
FOR PATIENTS AND PHYSICIANS

Designed to help gain & maintain a seal at the cervix.

**HTA ProCerva™ Procedure Sheath**  
for the HTA® System

The HTA ProCerva Procedure Sheath is designed to combine the effectiveness of the HTA System therapy with the added confidence of the new cervical seal assist, creating a treatment with reproducible results for both physicians and their patients.

**Boston Scientific**  
*Delivering what's next.™*

Refer to HTA System User's Manual provided with product for complete instructions for use.

**INDICATIONS:** The HTA System is a hysteroscopic thermal ablation device intended to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia (excessive uterine bleeding) due to benign causes for whom childbearing is complete. **CONTRAINDICATIONS:** The HTA System is contraindicated for use in a patient: who is pregnant or wants to be pregnant in the future, as pregnancy after ablation can be dangerous to both mother and fetus; who has known or suspected endometrial carcinoma or premalignant change of the endometrium, such as adenomatous hyperplasia; who has active pelvic inflammatory disease or pyosalpinx; hydrosalpinx; who has any anatomical or pathologic condition in which weakness of the myometrium could exist, such as, prior classic cesarean section or transmural myomectomy; who has an intrauterine device in place; or who has active genital or urinary tract infection, e.g., cervicitis, endometritis, vaginitis, cystitis, etc., at the time of treatment. **POTENTIAL ADVERSE EFFECTS** that may occur include: thermal injury to adjacent tissue including cervix, vagina, vulva, and/or perineum; heated saline escaping from the device system into the vascular spaces; hemorrhage; perforation of uterus; complications with pregnancy (Note: pregnancy following ablation is dangerous to both the mother and the fetus); risks associated with hysteroscopy, post ablation tubal sterilization syndrome: infection or sepsis; complications leading to serious injury or death. **WARNINGS:** NOTE: Failure to follow any instructions or to heed any Warnings or Precautions could result in serious patient injury. **CAUTION: Federal Law (USA) restricts this device to sale by or on the order of a physician. The physician using the device must be trained in diagnostic hysteroscopy.**

© 2009 Boston Scientific Corporation or its affiliates. All rights reserved. MVA410 5/09